ZA202204075B - Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof - Google Patents

Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Info

Publication number
ZA202204075B
ZA202204075B ZA2022/04075A ZA202204075A ZA202204075B ZA 202204075 B ZA202204075 B ZA 202204075B ZA 2022/04075 A ZA2022/04075 A ZA 2022/04075A ZA 202204075 A ZA202204075 A ZA 202204075A ZA 202204075 B ZA202204075 B ZA 202204075B
Authority
ZA
South Africa
Prior art keywords
addiction
treatment
cytisine
subjects
prevention
Prior art date
Application number
ZA2022/04075A
Other languages
English (en)
Inventor
A Jacobs Cindy
F Cain Daniel
Clarke Anthony
Original Assignee
Achieve Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achieve Life Sciences Inc filed Critical Achieve Life Sciences Inc
Publication of ZA202204075B publication Critical patent/ZA202204075B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2022/04075A 2019-09-12 2022-04-11 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof ZA202204075B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899637P 2019-09-12 2019-09-12
US202062988890P 2020-03-12 2020-03-12
PCT/US2020/046308 WO2021050203A1 (en) 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Publications (1)

Publication Number Publication Date
ZA202204075B true ZA202204075B (en) 2023-11-29

Family

ID=74866435

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/04075A ZA202204075B (en) 2019-09-12 2022-04-11 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Country Status (11)

Country Link
US (3) US11083715B2 (https=)
EP (1) EP4027815B1 (https=)
JP (2) JP7742832B2 (https=)
KR (1) KR20220074895A (https=)
CN (4) CN119564619A (https=)
AU (1) AU2020346695A1 (https=)
BR (1) BR112022004519A2 (https=)
CA (1) CA3153405A1 (https=)
MX (1) MX2022002882A (https=)
WO (1) WO2021050203A1 (https=)
ZA (1) ZA202204075B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119564619A (zh) * 2019-09-12 2025-03-07 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CA3230630A1 (en) * 2021-09-08 2023-03-16 Curtis SWIFT Analytical methods of assessing cytisine purity
JP2024095092A (ja) * 2022-12-28 2024-07-10 株式会社日立製作所 生成装置、生成方法、および生成プログラム
AU2024263979A1 (en) * 2023-04-26 2025-10-23 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002892A1 (fr) 1982-02-22 1983-09-01 Talapin, Vitaly, Ivanovich Preparation medicinale possedant un effet antinicotine et son procede d'obtention
EP0937077B1 (en) * 1996-10-30 2006-05-17 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CN102014995B (zh) * 2007-03-30 2015-05-13 菲利普莫里斯生产公司 用于输送药剂的装置和方法
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
EP3011026B1 (en) * 2013-06-21 2019-12-18 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
US20160199315A1 (en) * 2013-08-23 2016-07-14 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
PL409829A1 (pl) * 2014-10-18 2016-04-25 Łukasz Zalewski Płyn z cytyzyną do elektronicznych papierosów
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
KR102848174B1 (ko) * 2017-07-24 2025-08-27 어치브 파마 유케이 리미티드 시티신 염
CN119564619A (zh) * 2019-09-12 2025-03-07 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Also Published As

Publication number Publication date
KR20220074895A (ko) 2022-06-03
EP4027815A4 (en) 2023-06-07
JP2022548876A (ja) 2022-11-22
CN118286217A (zh) 2024-07-05
JP2025081331A (ja) 2025-05-27
US20210077473A1 (en) 2021-03-18
CN119587493A (zh) 2025-03-11
US11083716B2 (en) 2021-08-10
BR112022004519A2 (pt) 2022-05-31
US20210077475A1 (en) 2021-03-18
EP4027815A1 (en) 2022-07-20
AU2020346695A1 (en) 2022-04-28
WO2021050203A1 (en) 2021-03-18
US20210330652A1 (en) 2021-10-28
JP7742832B2 (ja) 2025-09-22
MX2022002882A (es) 2022-05-10
EP4027815B1 (en) 2026-04-15
CN119564619A (zh) 2025-03-07
CN114727647A (zh) 2022-07-08
US11083715B2 (en) 2021-08-10
CA3153405A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
ZA202204075B (en) Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
HK1252937A1 (zh) 用於治疗抑郁症的方法和试剂盒
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MY187540A (en) Compounds active towards bromodomains
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MY196631A (en) Antibody Agents Specific for Human Cd19 and uses Thereof
WO2016025635A3 (en) Combination therapy for treating cancer
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2017002489A (es) Agentes terapeuticos humanos.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
MX2017014436A (es) Compuestos biciclicos.
HK1258276A1 (zh) 用於治疗hiv的化合物和组合
MX2020011817A (es) Metodos para tratar el linfoma.
TW201713323A (en) Therapeutic compositions and methods of use thereof
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
MX2017013047A (es) Tratamiento de dolor.
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
MX2018002047A (es) Uso de ureidomustina (bo-1055) en el tratamiento del cancer.
PH12017500505A1 (en) Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers
WO2024226736A3 (en) Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject